Gossamer Bio (NASDAQ:GOSS) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2028 earnings at $0.30 EPS. Separately, Wedbush reaffirmed an outperform rating and […]
More Stories
Cheniere Energy Partners (CQP) & Its Competitors Financial Analysis
Cheniere Energy Partners (NYSE:CQP – Get Free Report) is one of 23 publicly-traded companies in the “Natural gas distribution” industry,...
Xos, Inc. (NASDAQ:XOS) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Xos, Inc. (NASDAQ:XOS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six...
Oruka Therapeutics (NASDAQ:ORKA) & Myriad Genetics (NASDAQ:MYGN) Critical Review
Myriad Genetics (NASDAQ:MYGN – Get Free Report) and Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) are both small-cap medical companies,...
AptarGroup, Inc. (NYSE:ATR) Receives $189.50 Average Target Price from Analysts
AptarGroup, Inc. (NYSE:ATR – Get Free Report) has been given an average rating of “Buy” by the seven analysts that...
Comparing VirTra (NASDAQ:VTSI) and Multi Ways (NYSE:MWG)
VirTra (NASDAQ:VTSI – Get Free Report) and Multi Ways (NYSE:MWG – Get Free Report) are both small-cap aerospace companies, but...
CAE Inc. (NYSE:CAE) Given Average Rating of “Hold” by Brokerages
CAE Inc. (NYSE:CAE – Get Free Report) (TSE:CAE) has earned an average recommendation of “Hold” from the nine brokerages that...